• how long it has been occurring
• if it gets worse at a particular point in the day
•Do you get chest pain, palpitations or ankle swelling?
•Does it come on or get worse when you lie flat?
•Does anything bring it on? For example, pollen, pets or medication?
•Do you smoke?
•Do you also have a cough, or bring up phlegm?
•How active are you usually?
•What’s your job or occupation?
•Is your breathlessness related to certain times at work?
•Do you have a history of heart, lung or thyroid disease or of anaemia?
•Have you made any changes in your life because of your shortness of breath?
•Do you feel worried or frightened, depressed or hopeless?
•What have you done to help you cope with the way you’re feeling?
•Does it come and go or is it there all the time?
•Is there any pattern to your breathlessness?
Answer:
He is looking for maintenance and reliability quality
Explanation:
He is worried that the product will be reliable and able to be maintained regularly when or if broken.
Search Results
Featured snippet from the web
The main difference between EHR and PHR systems is that EHR systems are manged by health care providers and PHR systems are used by the patient. The terms EHR, PHR, and even electronic medical record (EHR), are frequently used interchangeably, but are actually quite different.
In the intervention group, 212 women (5.7 per 10,000 person-years) and 176 (4.7 per 10,000 person-years) received an ovarian cancer diagnosis (rate ratio [RR], 1.21; 95% confidence interval [CI], 0.99-1.48).
In the intervention group, there were 118 ovarian cancer-related deaths (3.1 per 10,000 person-years), compared to 100 in the standard care group (mortality RR, 1.18; 95% CI, 0.82-1.71).
1080 of the 3285 women who had false-positive test results underwent surgical follow-up, and 163 of them (15%) had at least one significant consequence.
Except for ovarian, colorectal, and lung cancer, there were 2924 deaths from other causes (76.6 per 10 000 person-years) in the intervention group and 2914 deaths (76.2 per 10 000 person-years)
Simultaneous screening with CA-125 and transvaginal ultrasound in comparison to standard treatment did not lower ovarian cancer mortality among women in the general US population. Complications were linked to diagnostic examination after a false-positive screening test result.
To learn more about ovarian cancer here:-
brainly.com/question/25637266?referrer=searchResults
#SPJ4
